keyword
https://read.qxmd.com/read/38626388/modelling-structural-elements-and-functional-responses-to-lymphatic-delivered-cues-in-a-murine-lymph-node-on-a-chip
#1
JOURNAL ARTICLE
Corrado Mazzaglia, Hafsa Munir, Iek M Le, Magda Gerigk, Yan Yan Shery Huang, Jacqueline D Shields
Lymph nodes (LNs) are organs of the immune system, critical for maintenance of homeostasis and initiation of immune responses, yet there are few models that accurately recapitulate LN functions in vitro. To tackle this issue, an engineered murine LN (eLN) was developed, replicating key cellular components of the mouse LN; incorporating primary murine lymphocytes, fibroblastic reticular cells (FRCs), and lymphatic endothelial cells (LECs). T and B cells compartments are incorporated within the eLN that mimic LN cortex and paracortex architectures...
April 16, 2024: Advanced Healthcare Materials
https://read.qxmd.com/read/38615511/increased-co-expression-of-icos-and-pd-1-predicts-poor-overall-survival-in-patients-with-acute-myeloid-leukemia
#2
JOURNAL ARTICLE
Shiyi Pan, Qinghua Cai, Yiqiong Wei, Haifeng Tang, Yuping Zhang, Wei Zhou, Tingfen Deng, Wenjian Mo, Shunqing Wang, Caixia Wang, Cunte Chen
BACKGROUND: Inducible co-stimulatory factor (ICOS) has a dual role: activating cytotoxic T cells against tumors or exacerbating immunosuppression of regulatory T cells (Tregs) to participate in immune evasion. However, the correlation between ICOS and its co-expression with inhibitory immune checkpoints (IICs) and prognosis in acute myeloid leukemia (AML) is little known. METHODS: The prognostic importance of ICOS and IICs in 62 bone marrow (BM) samples of de novo AML patients from our clinical center (GZFPH) was explored and then the RNA sequencing data of 155 AML patients from the Cancer Genome Atlas (TCGA) database was used for validation...
April 11, 2024: Immunobiology
https://read.qxmd.com/read/38610607/flag-flag-ida-regimen-in-secondary-and-relapsed-refractory-acute-myeloid-leukemia-even-in-the-era-of-new-treatment-modalities-still-a-significant-player
#3
JOURNAL ARTICLE
Saša Anžej Doma, Matjaž Sever, Gorazd Jakoš, Helena Podgornik
(1) Background : Relapsed/refractory (r/r) and secondary acute myeloid leukemia are highlighted by chemoresistance and poor outcomes. The aim of the study was to assess the efficacy and toxicity of fludarabine, cytarabine, and granulocyte-colony stimulation factor (FLAG) with or without idarubicin (-Ida) and to discuss novel therapies in this setting. (2) Methods : Clinical and cytogenetic data on 130 consecutive patients with r/r and secondary AML treated at our center were retrospectively analyzed. (3) Results : There were 48, 56, and 26 patients with relapsed, refractory, and secondary AML, respectively...
March 22, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38609917/a-chest-ct-based-nomogram-for-predicting-survival-in-acute-myeloid-leukemia
#4
JOURNAL ARTICLE
Xiaoping Yi, Huien Zhan, Jun Lyu, Juan Du, Min Dai, Min Zhao, Yu Zhang, Cheng Zhou, Xin Xu, Yi Fan, Lin Li, Baoxia Dong, Xinya Jiang, Zeyu Xiao, Jihao Zhou, Minyi Zhao, Jian Zhang, Yan Fu, Tingting Chen, Yang Xu, Jie Tian, Qifa Liu, Hui Zeng
BACKGROUND: The identification of survival predictors is crucial for early intervention to improve outcome in acute myeloid leukemia (AML). This study aim to identify chest computed tomography (CT)-derived features to predict prognosis for acute myeloid leukemia (AML). METHODS: 952 patients with pathologically-confirmed AML were retrospectively enrolled between 2010 and 2020. CT-derived features (including body composition and subcutaneous fat features), were obtained from the initial chest CT images and were used to build models to predict the prognosis...
April 12, 2024: BMC Cancer
https://read.qxmd.com/read/38609396/validation-of-the-2022-european-leukemianet-risk-stratification-for-acute-myeloid-leukemia
#5
JOURNAL ARTICLE
Ga-Young Song, Hyeon-Jong Kim, TaeHyung Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Mihee Kim, Deok-Hwan Yang, Je-Jung Lee, Mi Yeon Kim, June-Won Cheong, Chul Won Jung, Jun Ho Jang, Hee- Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Seong Kyu Park, Sung-Hyun Kim, Chang Kyun Choi, Hyeoung-Joon Kim, Jae-Sook Ahn, Dennis Dong Hwan Kim
This study aimed to validate the 2022 European LeukemiaNet (ELN) risk stratification for acute myeloid leukemia (AML). A total of 624 newly diagnosed AML patients from 1998 to 2014 were included in the analysis. Genetic profiling was conducted using targeted deep sequencing of 45 genes based on recurrent driver mutations. In total, 134 (21.5%) patients had their risk classification reassessed according to the 2022 ELN risk stratification. Among those initially classified as having a favorable risk in 2017 (n = 218), 31 and 3 patients were reclassified as having intermediate risk or adverse risk, respectively...
April 12, 2024: Scientific Reports
https://read.qxmd.com/read/38591341/genetic-testing-for-supravalvar-aortic-stenosis-what-to-do-when-it-is-not-williams-syndrome
#6
JOURNAL ARTICLE
Sara B Stephens, Tyler Novy, Gabrielle N Spurzem, Benjamin Jacob, Taylor Beecroft, Emily Soludczyk, Beth A Kozel, Justin Weigand, Shaine A Morris
BACKGROUND: We aimed to describe the frequency and yield of genetic testing in supravalvar aortic stenosis (SVAS) following negative evaluation for Williams-Beuren syndrome (WS). METHODS AND RESULTS: This retrospective cohort study included patients with SVAS at our institution who had a negative evaluation for WS from May 1991 to September 2021. SVAS was defined as (1) peak supravalvar velocity of ≥2 meters/second, (2) sinotubular junction or ascending aortic Z score <-2...
April 9, 2024: Journal of the American Heart Association
https://read.qxmd.com/read/38580225/epr24-100-a-comparison-of-somatic-mutations-and-eln-classification-in-de-novo-acute-myeloid-leukemia-between-appalachian-and-non-appalachian-kentucky
#7
JOURNAL ARTICLE
Zena Chahine, Xitong Zhou, Anna Johnson, Trevor Morris, Ashley Soule, Hiffsa Taj, Claire McAvoy, Chaitanya Iragavarapu, Reinhold Munker, Gregory Monohan, Fevzi Yalniz, Ayman Qasrawi, Reshma Ramlal
No abstract text is available yet for this article.
April 5, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38577341/cd7-positive-leukemic-blasts-with-dnmt3a-mutations-predict-poor-prognosis-in-patients-with-acute-myeloid-leukemia
#8
JOURNAL ARTICLE
Yanliang Bai, Xiaobai Sun, Mengyi Li, Xiaona Niu, Weijie Cao, Junwei Niu, Xingjun Xiao, Yuqing Chen, Kai Sun
BACKGROUND: DNMT3A mutations can be detected in premalignant hematopoietic stem cells and are primarily associated with clonal hematopoiesis of indeterminate potential; however, current evidence does not support assigning them to a distinct European Leukemia Net (ELN) prognostic risk stratification. CD7 is a lymphoid antigen expressed on blasts in approximately 30% of acute myeloid leukemia (AML), and its role in AML remains unclear and depends on subgroup evaluation. This study investigated the prognostic value of DNMT3A mutation combined with CD7 expression in AML...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38572926/treatment-outcome-and-germline-predictive-factors-of-ropeginterferon-alpha-2b-in-myeloproliferative-neoplasm-patients
#9
JOURNAL ARTICLE
Chih-Cheng Chen, Ming-Chung Kuo, Ying-Hsuan Wang, Sung-Nan Pei, Ming-Lih Huang, Chiu-Chen Chen, Cih-En Huang, Yi-Yang Chen, Lee-Yung Shih
BACKGROUND: Studies have shown that some single nucleotide polymorphisms (SNPs) could serve as excellent markers in foretelling the treatment outcome of interferon (IFN) in myeloproliferative neoplasms (MPN). However, most work originated from western countries, and data from different ethnic populations have been lacking. METHODS: To gain insights, targeted sequencing was performed to detect myeloid-associated mutations and SNPs in eight loci across three genes (IFNL4, IFN-γ, and inosine triphosphate pyrophosphatase [ITPA]) to explore their predictive roles in our cohort of 21 ropeginterferon alpha-2b (ROPEG)-treated MPN patients, among whom real-time quantitative PCR was also performed periodically to monitor the JAK2V617F allele burden in 19 JAK2V617F-mutated cases...
April 2024: Cancer Medicine
https://read.qxmd.com/read/38563130/oral-exosome-like-nanovesicles-from-phellinus-linteus-suppress-metastatic-hepatocellular-carcinoma-by-reactive-oxygen-species-generation-and-microbiota-rebalancing
#10
JOURNAL ARTICLE
Menghang Zu, Ga Liu, Nanxi Chen, Li Chen, Qiang Gao, Rui L Reis, Subhas C Kundu, Meilan Jin, Bo Xiao, Xiaoxiao Shi
The biomedical application of nanotechnology in cancer treatment has demonstrated significant potential for improving treatment efficiencies and ameliorating adverse effects. However, the medical translation of nanotechnology-based nanomedicines faces challenges including hazardous environmental effects, difficulties in large-scale production, and possible excessive costs. In the present study, we extracted and purified natural exosome-like nanoparticles (ELNs) from Phellinus linteus . These nanoparticles (denoted as P-ELNs) had an average particle size of 154...
April 2, 2024: Nanoscale
https://read.qxmd.com/read/38544823/exploring-the-role-of-non-synonymous-and-deleterious-variants-identified-in-colorectal-cancer-a-multi-dimensional-computational-scrutiny-of-exomes
#11
JOURNAL ARTICLE
Chandrashekar Karunakaran, Vidya Niranjan, Anagha S Setlur, Dhanya Pradeep, Jitendra Kumar
INTRODUCTION: Colorectal cancers are the world's third most commonly diagnosed type of cancer. Currently, there are several diagnostic and treatment options to combat it. However, a delay in detection of the disease is life-threatening. Additionally, a thorough analysis of the exomes of cancers reveals potential variation data that can be used for early disease prognosis. METHODS: By utilizing a comprehensive computational investigation, the present study aimed to reveal mutations that could potentially predispose to colorectal cancer...
February 23, 2024: Current Genomics
https://read.qxmd.com/read/38506267/comparison-of-clinical-outcomes-of-several-risk-stratification-tools-in-newly-diagnosed-aml-patients-a-real-world-evidence-in-our-current-therapeutic-era
#12
JOURNAL ARTICLE
Alexandre Iat, Michael Loschi, Sami Benachour, Anne Calleja, Edmond Chiche, Isabelle Sudaka, Danièle Aquaronne, Corinne Ferrero, Laurène Fenwarth, Alice Marceau, Elise Fournier, Berengere Dadone-Montaudie, Thomas Cluzeau
BACKGROUND OF THE STUDY: AML classification tools have been developed to stratify the risk at AML diagnosis. There is a need to evaluate these tools in the current therapeutic era. COHORT CHARACTERISTICS: In this retrospective study, we compared five classifiers: ELN 2017, ELN 2022, ALFA classifier, Papaemmanuil et al. classifier, and Lindsley et al. classifier, in a real-life cohort of 281 patients newly diagnosed for AML in Nice University Hospital. In our cohort median age was 68 years old, sex ratio was M/F 56%/44%, performance status was lower than 2 in 73...
March 2024: Cancer Medicine
https://read.qxmd.com/read/38470375/venetoclax-plus-a-hypomethylating-agent-versus-cytarabine-aclarubicin-and-granulocyte-colony-stimulating-factor-chemotherapy-as-a-first-line-therapy-for-newly-diagnosed-acute-myeloid-leukemia-a-propensity-score-matched-analysis
#13
JOURNAL ARTICLE
Rui Huang, Honghua He, Xiaoli Xu, Xiaonan Lin, Ying Dong, Xiaotao Wang, Fang Jiang, Pengcheng Huang, Shuyi Mo, Zhenqian Huang, Yaya Wang, Hongfang Tao, Yaling Zheng, Ming Wu, Chuting Yang, Ziyu Zheng, Ying Zhao, Yuming Zhang, Yuhua Li
BACKGROUND: Both venetoclax plus a hypomethylating agent (VEN/HMA) and cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CAG) are low-intensity regimens for older patients with acute myeloid leukemia (AML) that show good efficacy and safety. It is unknown how VEN/HMA compares with the CAG regimen for the treatment of newly diagnosed AML. METHODS: The outcomes of patients with newly diagnosed AML treated with VEN/HMA were compared with those of patients treated with a CAG-based regimen...
March 12, 2024: Cancer
https://read.qxmd.com/read/38469782/development-of-a-low-cost-semiquantitative-polymerase-chain-reaction-assay-for-molecular-diagnosis-of-williams-syndrome
#14
JOURNAL ARTICLE
Dinali M Ranaweera, Deepthi C de Silva, Duminda Samarasinghe, Shehan Perera, Nirosha Kugalingam, Sumudu R Samarasinghe, Wadumesthri Y Madushani, Hiran H E Jayaweera, Siyath Gunewardene, Kajan Muneeswaran, Vaz S Gnanam, Naduviladath V Chandrasekharan
BACKGROUND: Williams Beuren Syndrome (WBS) is a well-recognized and common genetic cause of congenital heart defects, developmental delay, hypercalcemia, and characteristic facial features. It is caused by a 1.5 - 1.8 Mb heterozygous deletion of chromosome 7q11.23 with loss of around 28 coding genes. The aim of this study was to develop a low-cost, semi-quantitative PCR (sqPCR) method to detect the chromosome 7q11.23 deletion. METHODS: Twenty-four suspected WBS cases were recruited following ethical clearance and informed consent...
March 1, 2024: Clinical Laboratory
https://read.qxmd.com/read/38461563/microscopic-chemical-characterization-of-epoxy-resin-with-scanning-transmission-electron-microscopy-electron-energy-loss-spectroscopy
#15
JOURNAL ARTICLE
Hsin-Hui Huang, Tomohiro Miyata, Yohei K Sato, Teruyasu Mizoguchi, Hiroshi Jinnai, Kaname Yoshida
The structural characterization of epoxy resins is essential to improve the understanding on their structure-property relationship for promising high-performance applications. Among all analytical techniques, scanning transmission electron microscopy-electron energy-loss spectroscopy (STEM-EELS) is a powerful tool for probing the chemical and structural information of various materials at a high spatial resolution. However, for sensitive materials, such as epoxy resins, the structural damage induced by electron-beam irradiation limits the spatial resolution in the STEM-EELS analysis...
March 7, 2024: Micron
https://read.qxmd.com/read/38445193/severe-atopic-dermatitis-with-cutis-laxa-caused-by-a-variant-in-the-eln-gene
#16
Tatsuya Katsumi, Ryota Hayashi, Shingo Takei, Rei Yokoyama, Osamu Ansai, Satoru Shinkuma, Riichiro Abe
No abstract text is available yet for this article.
April 2024: JAAD Case Reports
https://read.qxmd.com/read/38438627/rop-et-a-prospective-phase-iii-trial-investigating-the-efficacy-and-safety-of-ropeginterferon-alfa-2b-in-essential-thrombocythemia-patients-with-limited-treatment-options
#17
JOURNAL ARTICLE
Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer-Ausch, Olga Cerna, Ana-Manuela Crisan, Catalin Doru Danaila, Valerio De Stefano, Konstanze Döhner, Victoria Empson, Joanna Gora-Tybor, Martin Griesshammer, Sebastian Grosicki, Paola Guglielmelli, Valentin García-Gutierrez, Florian H Heidel, Arpád Illés, Ciprian Tomuleasa, Chloe James, Steffen Koschmieder, Maria-Theresa Krauth, Kurt Krejcy, Mihaela-Cornelia Lazaroiu, Jiri Mayer, Zsolt György Nagy, Franck-Emmanuel Nicolini, Francesca Palandri, Vassiliki Pappa, Andreas Johannes Reiter, Tomasz Sacha, Stefanie Schlager, Stefan Schmidt, Evangelos Terpos, Martin Unger, Albert Wölfler, Blanca Xicoy Cirici, Christoph Klade
Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they do not modify the natural history of the disease and hence, have no impact on disease progression. Ropeginterferon alfa-2b (trade name BESREMi®), a novel, monopegylated interferon alfa-2b with an extended administration interval, has demonstrated a robust and sustained efficacy in polycythemia vera (PV) patients...
March 4, 2024: Annals of Hematology
https://read.qxmd.com/read/38433437/prognostic-analysis-according-to-european-leukemianet-2022-risk-stratification-for-elderly-patients-with-acute-myeloid-leukemia-treated-with-decitabine
#18
JOURNAL ARTICLE
Mihee Kim, Seo-Yeon Ahn, TaeHyung Kim, Sung-Hoon Jung, Ga-Young Song, Deok-Hwan Yang, Je-Jung Lee, Mi Yeon Kim, Ju Heon Park, Myung-Geun Shin, Jae-Sook Ahn, Hyeoung-Joon Kim, Dennis Dong Hwan Kim
OBJECTIVES: This study aimed to evaluate the prognostic significance of the revised European LeukemiaNet (ELN)-2022 risk stratification model for 123 elderly acute myeloid leukemia (AML) patients treated with decitabine chemotherapy. RESULTS: Based on the ELN-2022 risk stratification, 15 (12.2%), 51 (41.5%), and 57 (46.3%) patients were classified as having favorable, intermediate, and high-risk AML, respectively. In comparison with the ELN-2017 risk stratification, the ELN-2022 risk stratification re-assigned 26 (21...
December 2024: Hematology (Amsterdam, Netherlands)
https://read.qxmd.com/read/38422768/the-xpo1-inhibitor-selinexor-ameliorates-bleomycin-induced-pulmonary-fibrosis-in-mice-via-gbp5-nlrp3-inflammasome-signaling
#19
JOURNAL ARTICLE
Jia Zhang, Yihua Zhang, Qi Chen, Yong Qi, Xiaoju Zhang
Pulmonary fibrosis is an irreversible and progressive lung disease with limited treatments available. Selinexor (Sel), an orally available, small-molecule, selective inhibitor of XPO1, exhibits notable antitumor, anti-inflammatory and antiviral activities. However, its potential role in treating pulmonary fibrosis is unknown. C57BL/6J mice were used to establish a pulmonary fibrosis model by intratracheal administration of bleomycin (BLM). Subsequently, Sel was administered intraperitoneally. Our data demonstrated that Sel administration ameliorated BLM-induced pulmonary fibrosis by increasing mouse body weights; reducing H&E staining, Masson staining scores, and shadows in mouse lung computed tomography (CT) images, decreasing the total cell and neutrophil counts in the lung and bronchoalveolar lavage fluid (BALF); and decreasing the levels of TGF-β1...
February 28, 2024: International Immunopharmacology
https://read.qxmd.com/read/38411364/use-of-onenote-class-notebook-as-a-combined-electronic-laboratory-notebook-and-content-delivery-tool-in-an-introductory-biochemistry-laboratory-course
#20
JOURNAL ARTICLE
Ahlia Khan-Trottier
The COVID-19 pandemic has forced a shift in thinking regarding the safe delivery of wet laboratory courses. While we were fortunate to have the capacity to continue delivering wet laboratory experiments with physical distancing and other measures in place, modifications to the mechanisms of delivery within courses were necessary to minimize risk to students and teaching staff. One such modification was introduced in BCH370H, an introductory biochemistry laboratory course, where a OneNote Class Notebook (ONCN) was used as an electronic laboratory notebook (ELN) in place of the traditional hardbound paper laboratory notebook (PLN) used prior to the pandemic...
February 27, 2024: Biochemistry and Molecular Biology Education
keyword
keyword
161229
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.